(RTTNews) – MannKind Corp. (MNKD) announced FDA approval for Furoscix ReadyFlow, an autoinjector for edema treatment in adults with heart failure or chronic kidney disease. The device demonstrates intravenous-equivalent pharmacokinetic outcomes and improved patient comfort compared to traditional methods.
Clinical data confirm Furoscix ReadyFlow achieves comparable therapeutic effects to intravenous Furosemide, with favorable safety profiles. Patients experienced symptom relief within an hour of administration, supporting its potential as a convenient at-home solution.
The company plans to release the autoinjector in the U.S. by August 2026, building on the 2022 FDA approval of its on-body infusor. This expansion adds a faster, more user-friendly option to MannKind’s Furoscix product line.
In parallel, MannKind executed a private placement raising $50 million through the issuance of 10.44 million shares at $3.89 each and pre-funded warrants. Proceeds will support general corporate operations and cover a $45 million contingent value rights payment linked to the drug’s approval.
Frazier Life Sciences led the financing, with closing anticipated by July 24, 2026, contingent on standard conditions. MNKD shares rose 4.57% to $4.06 following the announcement.
Also Read
- Current Mortgage Rates Reach 2026 High on July 24, 2026
- Kenny Chesney Secures Historic All-Time No. 1 on Country Airplay Chart
- Ukrainian Strikes Hit Russian E-commerce Giant’s Warehouses Amid Ongoing Conflict
- Wisconsin Initiates Homicide Investigation Following Fatal Police Shooting of 38-Year-Old Man
